You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

24 Results
Guidelines and Advice
Status: Archived
ID: 2-7
Version: 2
Jan 2016
Guidelines and Advice
Status: Archived
ID: 12-17
Feb 2016
Guidelines and Advice
Drug
Other Name(s): Temodal®
Aug 2025
Drug
Other Name(s): Mekinist®
Jun 2025
Regimen
Cancer Type:
Central Nervous System
Intent: Palliative
Funding:
ODB - General Benefit
    temozolomide
Aug 2025
Regimen
Intent: Palliative
Funding:
Exceptional Access Program
    trametinib - As monotherapy in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, according to specific criteria
Jun 2025
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Jul 2025
Regimen
Cancer Type:
Central Nervous System
Intent: Adjuvant
Funding:
ODB - General Benefit
    temozolomide
Aug 2025
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    tamoxifen
Sep 2025
Drug
Other Name(s): Tukysa™
Feb 2025
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Tebentafusp (Outpatient) - Unresectable or Metastatic Uveal Melanoma
High Cost Therapy Funding Program
    Tebentafusp (Inpatient) - Unresectable or Metastatic Uveal Melanoma
Aug 2025

Pages